Merus N.V. Announces Proposed Public Offering of Common Shares
28 mai 2024 16h01 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing...
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
28 mai 2024 07h00 HE
|
Merus N.V.
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V....
Vorläufige Ergebnisse von Merus zu Petosemtamab in Kombination mit Pembrolizumab zeigen robuste Ansprechrate und günstiges Sicherheitsprofil bei Erstlinienbehandlung von rezidivierendem/metastasierendem HNSCC
28 mai 2024 07h00 HE
|
Merus N.V.
67 % Ansprechrate bei 24 auswertbaren Patienten beobachtet Telefonkonferenz am Dienstag, 28. Mai um 8 Uhr Eeastern Time UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 28, 2024 (GLOBE...
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent un taux de réponse important et un profil d’innocuité favorable dans le traitement de première ligne du CETC r/m
28 mai 2024 07h00 HE
|
Merus N.V.
Taux de réponse de 67 % observé chez les 24 patients évaluables Conférence téléphonique le mardi 28 mai à 8 h, heure de l’Est UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 28 mai 2024 (GLOBE...
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
23 mai 2024 17h00 HE
|
Merus N.V.
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster...
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
23 mai 2024 17h00 HE
|
Merus N.V.
- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed - ...
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
13 mai 2024 08h00 HE
|
Merus N.V.
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage...
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
08 mai 2024 16h15 HE
|
Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by...
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
06 mai 2024 16h05 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
08 avr. 2024 12h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...